RITOBEGRON

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H27NO5
Molecular Weight	373.4428
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](NCCC1=CC(C)=C(OCC(O)=O)C=C1C)[C@H](O)C2=CC=C(O)C=C2

InChI

InChIKey=VMMYRRFPMAGXNP-BTYIYWSLSA-N

InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800018190 | https://clinicaltrials.gov/ct2/show/NCT02256722 | https://clinicaltrials.gov/ct2/show/NCT02259751 | https://www.ncbi.nlm.nih.gov/pubmed/25975097

Ritobegron (KUC 7483) is a selective β3-adrenoceptor agonist that was developed for oral treatment of overactive bladder. It is the prodrug of the active compound KUC-7322. Phase I studies have investigated the pharmacodynamic and pharmacokinetic effects of ritobegron in healthy individuals and patients with spinal cord injury. Ritobegron exhibits a high selectivity for the bladder versus other organs, and decreased intravesical pressure with minimal effects on the cardiovascular system in rats. When administered in combination with organic anion transporter (OAT) inhibitors such as probenecid (primarily used in treating gout and hyperuricemia), the plasma concentration of the active compound KUC-7322 may increase.

Approval Year

Name

Type

Language

RITOBEGRON

Official Name

English

KUC-7483

Code

English

ritobegron [INN]

Common Name

English

(4-(2-(((1R,2S)-1-HYDROXY-1-(4-HYDROXYPHENYL)PROPAN-2-YL)AMINO)ETHYL)-2,5-DIMETHYLPHENOXY)ACETIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C48149